| Document |
Document Title |
|
WO/2011/002520 |
Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP- ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial inf...
|
|
WO/2011/002520 |
Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP- ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial inf...
|
|
WO/2010/151042 |
The present invention relates to a composition which contains Schizandra chinensis Baillon and Chaenomeles sinensis extracts as active ingredients for alleviating muscle fatigue and muscle pain or for enhancing exercise capability. The c...
|
|
WO/2010/151840 |
This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
|
|
WO/2010/151042 |
The present invention relates to a composition which contains Schizandra chinensis Baillon and Chaenomeles sinensis extracts as active ingredients for alleviating muscle fatigue and muscle pain or for enhancing exercise capability. The c...
|
|
WO/2010/148010 |
The present invention provides chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a...
|
|
WO/2010/147226 |
Provided is a compound having a serotonin 5-HT2c receptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I0): wherein each symbol is as defined in the specificatio...
|
|
WO/2010/146622 |
Provided are drugs, external preparations and cosmetics having an effect of inhibiting NFAT signal, an effect of inhibiting calcineurin and an effect of promoting hair growth. An NFAT signal inhibitor which comprises as the active ingred...
|
|
WO/2010/140685 |
Disclosed is an amplifier for hematopoietic stem cells and/or hematopoietic progenitor cells which is useful for treating various diseases and for improving the efficiency of transferring a gene into hematopoietic stem cells in gene ther...
|
|
WO/2010/136508 |
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...
|
|
WO/2010/137349 |
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a s...
|
|
WO/2010/137350 |
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (Ia) or (Ib), a pharmaceutically acceptable salt there...
|
|
WO/2010/138670 |
Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.
|
|
WO/2010/136508 |
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...
|
|
WO/2010/138670 |
Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.
|
|
WO/2010/137351 |
The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tet...
|
|
WO/2010/132982 |
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...
|
|
WO/2010/134047 |
The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.
|
|
WO/2010/131382 |
Disclosed is a muscle repair promoter for local administration, which comprises a granulocyte-colony stimulating factor (G-CSF) as an active ingredient. The muscle repair promoter can exhibit the efficacy thereof at a small dose particul...
|
|
WO/2010/130799 |
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...
|
|
WO/2010/131712 |
Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a com...
|
|
WO/2010/130799 |
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...
|
|
WO/2010/129406 |
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...
|
|
WO/2010/129273 |
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
|
|
WO/2010/128243 |
The present invention relates to a method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50%, including a step of purifying a raw spinach extract in a liquid fo...
|
|
WO/2010/129273 |
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
|
|
WO/2010/129406 |
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...
|
|
WO/2010/125271 |
The invention relates to a gas mixture that contains nitrous oxide (N2O) for use as a breathable drug for the treatment of chronic pain in a mammal, in particular a pain from neuropathic, iatrogenic, dysfunctional or inflammatory origin,...
|
|
WO/2010/124365 |
There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells,...
|
|
WO/2010/125799 |
Disclosed is a compound represented by formula (I), which inhibits the action of PI3K, controls a number of biological processes, such as the growth, differentiation, survival, proliferation, migration and metabolism of cells, and, there...
|
|
WO/2010/126167 |
Disclosed are: a compound represented by formula (I), or a salt, solvate or physiologically functional derivative thereof; and a pharmaceutical composition comprising the compound or the salt, solvate or physiologically functional deriva...
|
|
WO/2010/124520 |
The pharmaceutical compositions for treating abnormal energy metabolism, comprising a) medicines for promoting oxidation of fatty acid or derivatives thereof, particularly levocarnitine, and b) medicines for promoting oxidation of glucos...
|
|
WO/2010/126104 |
Disclosed is a novel pyridazinone compound having an activity of inhibiting P2X7 receptor that is a kind of purine receptor, which is useful in preventing, treating or ameliorating diseases relating to inflammation or immunity. Specifica...
|
|
WO/2010/125348 |
The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertat...
|
|
WO/2010/121324 |
The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and ...
|
|
WO/2010/123243 |
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...
|
|
WO/2010/123243 |
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...
|
|
WO/2010/118675 |
The present invention reveals a new use of neferine. Neferine regulates M8 and V1 subtype of transient receptor potential ion channel (TRPM8 and TRPV1), respectively, in mammals, including humans, and can be used for preparing medicament...
|
|
WO/2010/121225 |
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...
|
|
WO/2010/119875 |
Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable c...
|
|
WO/2010/118699 |
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.
|
|
WO/2010/121225 |
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...
|
|
WO/2010/116673 |
Disclosed are a novel mitochondrial function-improving agent and a novel PGC-1α expression inducer. Specifically disclosed are a mitochondrial function-improving agent and a PGC-1α expression inducer, each of which comprises a lysine-s...
|
|
WO/2010/113225 |
The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Fur...
|
|
WO/2010/113834 |
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...
|
|
WO/2010/112091 |
Compounds of formula (I) wherein R1, R2, R3, X, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/112093 |
Compounds of formula (I), wherein R1, R2, R3, X and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/112092 |
Compounds of formula (I) wherein R1, R2, R3, R4, L1, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/108843 |
The present invention relates to the use of nitric oxide releasing derivatives of paracetamol for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.
|
|
WO/2010/109386 |
|
